Real‐world evidence of F‐fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System
- Published on 07/25/2024
- Reading time: 4 min.
Nadine A. Friedrich MD 1, Lin Gu MS 2, Justin Waller MS 2, Amanda M. De Hoedt MS 2, Zachary Klaassen MD, MSc 2,3,4, Stephen J. Freedland MD 1,2
1
Division of Urology, Department of Surgery
Cedars‐Sinai Medical Center
Los Angeles
California
USA
2 Durham Veterans Affairs Health Care System
Durham
North Carolina
USA
3
Division of Urology, Department of Surgery, Medical College of Georgia
Augusta University
Augusta
Georgia
USA
4 Georgia Cancer Center
Augusta
Georgia
USA
Abstract
Background There are no population‐level studies assessing 18F‐fluciclovine (fluciclovine) utilization of Positron emission tomography/computed tomography (PET/CT) for biochemically recurrent prostate cancer (PC). We assessed fluciclovine PET/CT in the Veterans Affairs Health Care System.
Methods Of 1153 men with claims suggesting receipt of fluciclovine PET/CT, we randomly reviewed charts of 300 who indeed underwent fluciclovine...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology